Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03733496 · ClinicalTrials.gov registry record
Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
A clinical trial, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- 14
- Enrollment target
NCT03733496: Completed study, sponsored by Neurocrine Biosciences.
NCT03733496 is a clinical trial that has completed, run by Neurocrine Biosciences. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03733496 has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
An extension study for participants who have completed a prior VY-AADC01 clinical study
Primary Outcome
Long-term safety of VY-AADC01 as measured by Adverse Events and Serious Adverse Events
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-08-24 |
| Est. Completion | 2023-07-18 |
What the finished NCT03733496 record still lists
NCT03733496 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03733496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03733496 about?
NCT03733496 is a clinical study titled "Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies". An extension study for participants who have completed a prior VY-AADC01 clinical study
What is the current status of trial NCT03733496?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2018-08-24. Estimated completion is 2023-07-18.
Who is sponsoring clinical trial NCT03733496?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy